Introduction: A novel growth factor allograft shown to provide the complete growth factor payload provided by the donor tissue was utilized to support interbody fusion with patients requiring minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) procedures.
Methods: An Institutional Review Board granted a waiver to
retrospectively assess fusion results for patients receiving novel growth
factors in supporting MI-TLIF procedures. Radiology produced during standard
post-surgical follow-up was de-identified and independently reviewed by an
accredited Radiologist for the state of fusion according to Brantigan, Steffee
and Fraser criteria.
Results: At three months, 72 of 104 (69.2%) levels assessed were
deemed to be fully fused, at six months 87 of 116 (75.0%) levels assessed were
deemed to be fused, at twelve months 107 of 113 (94.7%) levels assessed were
deemed to be fused, at eighteen months 107 of 109 (98.2%) levels assessed were
deemed to be fused and ultimately at twenty-one months all 108 of 108 (100%)
levels reviewed were deemed to be fully fused.
Conclusion: Novel growth factor allograft used to support MI-TLIF
procedures provides a safe and effective alternative to supporting healthy bony
remodeling desired with interbody fusion.
Author
(s) Details
S. Joseph
Department of Orthopaedics, Joseph Spine Institute, Tampa, Florida, USA.
L. Edge
Department of Orthopedic Surgery, HCA Healthcare / USF Morsani College of
Medicine GME: HCA Florida Largo Hospital, Largo, Florida, USA.
Please see the book here:- https://doi.org/10.9734/bpi/acmms/v10/3492
No comments:
Post a Comment